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ABSTRACT 
Aims: Mast cells are versatile innate immune cells and are reported to promote vascular 
inflammation and neointimal lesion formation, thereby contributing to the development of 
vascular stenosis and atherosclerosis. However, it is not clear whether mast cells also regulate 
vascular matrix remodelling in established neointima. This study addressed the hypothesis 
that perivascular mast cells regulate neointimal matrix remodelling using a mouse vein graft 
model. Methods: The impact of mast cells on neointimal remodelling was investigated using 
      
 
mast cell-deficient animals in both normolipidaemic (KitW-sh/W-sh) and hyperlipidaemic (apoE-
/-KitW-sh/W-sh) conditions. The effect of perivascular mast cells on vascular matrix remodelling, 
including collagen and elastin deposition, was investigated using a local mast cell 
reconstitution method that selectively repopulated mast cells around the carotid artery (where 
the vein graft was inserted) in KitW-sh/W-sh mice. Results: In normolipidaemic vein grafts 
(KitW-sh/W-sh vs. the wild type control C57BL/6J), collagen synthesis was not affected by mast 
cell deficiency at 4 weeks. In contrast, neointimal elastin was reduced by 6.5-fold in mast 
cell-deficient KitW-sh/W-sh mice, which was prevented by perivascular mast cell reconstitution. 
Mast cell deficiency induced a similar reduction in neointimal elastin in hyperlipidaemic 
mice (apoE-/-KitW-sh/W-sh vs. apoE-/-), with a significant increase in cell proliferation and 
neointimal area at 4 week. Conclusion: Mast cells appear to promote elastin deposition in 
vein grafts and this may lead to further suppression of cell proliferation and neointimal 
thickening under hyperlipidaemic conditions. 
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INTRODUCTION 
Mast cells are versatile innate immune cells, well-known for their role in inflammation and 
innate immunity.[1,2] Despite the wide distribution of mast cells in arterial adventitia and 
perivascular connective tissue, our understanding of the influence of mast cells in vascular 
disease is limited. In recent years, accumulating evidence suggests that mast cells promote 
vascular inflammation and contribute to the progression of a number of vascular diseases 
including atherosclerosis, aortic aneurysm and vein graft neointima hyperplasia.[3-6] Systemic 
activation of mast cells using dinitrophenyl-albumin increased plaque size in apoE-/- mice, 
whilst selective stimulation of perivascular mast cells had no impact on plaque formation but 
destabilised established plaque with increased intra-plaque haemorrhage.[7] Compound 48/80, 
another mast cell activator, demonstrated a similar effect to promote atherosclerosis 
development, which was inhibited by the mast cell stabiliser cromolyn.[8,9] In addition to 
pharmacological manipulation of mast cell function, studies using genetic mast cell 
deficiency (as a consequence of spontaneous mutation in the promoter region of the c-kit 
gene[10]) also confirmed the detrimental effect of mast cells in atherosclerosis.[3] Mechanistic 
studies revealed that activated mast cells synthesised and released a wide range of pro-
inflammatory factors including interleukin (IL)-6 and IL-8, interferon gamma, tumour 
necrosis factor alpha, histamine, chymase and tryptase. Consequently, mast cells exacerbated 
      
 
vascular inflammation with increased intra-plaque leukocyte infiltration, lipid uptake, 
vascular matrix degradation and subsequent plaque expansion and destabilisation.[6]  
 
In vein graft disease, neointimal hyperplasia is the major cause of restenosis.[11,12] The 
neointima formation in vein grafts is mainly driven by acute vascular inflammation. In a 
mouse vein graft model, the acute inflammation usually lasts less than two weeks following 
grafting surgery.[13,14] The neointima thereafter undergoes a remodelling stage where 
neointimal cells differentiate into smooth muscle-like cells and synthesise large amount of 
vascular matrix including collagen and elastin as a process of arterialisation.[12,15] The 
remodelling process stabilises neointimal cells and prevents chronic neointimal thickening. 
We and others have found that perivascular mast cells boost acute vein graft inflammation via 
an increase in cytokine secretion and activation of the complement system.[14,16] This leads to 
a significant rise in cell proliferation in the acute inflammation stage (one week after vein 
graft implantation) and more neointima formation. However, it is not clear whether 
perivascular mast cells also regulate vascular matrix remodelling after resolution of acute 
inflammation. This is particularly important under pro-atherosclerotic conditions as vascular 
smooth muscle cells from pro-atherosclerotic animals are more susceptible to chronic 
proliferation in response to mitogenic stimuli.[17] In the present study, we performed 
interpositional vein grafting in mast cell deficient mouse lines bred on both a 
normolipidaemic and hyperlipidaemic genetic background (KitW-sh/W-sh and apoE-/- KitW-sh/W-sh) 
to address this question.  
 
METHODS  
Animals 
All experiments which involved animals conformed to Directive 2010/63/EU of the European 
Parliament and also to the UK Home Office Animal (Scientific Procedures) Act 1986 and 
were performed under Project Licence PPL 60/4114. In addition, ethical permission for the 
study had been granted by the University of Strathclyde ethical review committee.  
 
Mice carrying the KitW-sh/W-sh mutation were used in this study as a mast cell deficiency 
model. KitW-sh/W-sh is a spontaneous mutation in the promoter region of the c-kit gene which is 
critical for mast cell survival.[10] As the c-kit gene itself is intact, c-kit expression is preserved 
to some extent in the early life of these mice. Consequently, systemic mast cell deficiency 
does not develop until 4 weeks old. Jackson Laboratories (USA) was the original supplier of 
      
 
both the KitW-sh/W-sh and apoE-/- mice and these were subsequently bred in-house. Both strains 
were on a C57BL/6J background. In order to generate a hyperlipidaemic mouse line lacking 
mast cells, apoE-/- andKitW-sh/W-sh mice were cross-bred. For the normolipidaemic KitW-sh/W-sh 
mice, the congenic control was C57BL/6J while for the hyperlipidaemic apoE-/- KitW-sh/W-sh 
mice, the apoE-/- was the congenic control. All mice were maintained on a cycle of 12-h 
periods of light and dark and allowed access to normal chow diet and water ad libitum. Male 
mice (about 10 to 20 weeks old) were used in this study. 
 
Surgery 
The mouse vein graft model is a well-established model for studying neointimal 
hyperplasia.[13,14] Briefly, i.p. injection of sodium pentobarbital (60 mg/kg) was used as an 
anaesthetic agent with top-up doses administered as appropriate and depending on the depth 
of anaesthesia demonstrated by the pedal withdrawal reflex. All animals received 
perioperative analgesic cover (buprenorphine; 0.05 mg/kg body weight, s.c.). From a donor 
mouse, the thoracic inferior vena cava was carefully harvested. In all experiments the donor 
mouse was a male mouse of the same genotype. In the recipient mouse, the right common 
carotid artery was prepared by isolating it, tying two sutures around the middle and cutting. A 
nylon cuff was then sleeved onto the distal arterial end. In order to graft the vein onto artery 
rather than nylon cuff, the artery was everted back over the cuff and ligated using 8/0 silk 
suture (Ethicon, Livingston, UK). The proximal end of the carotid artery was prepared in an 
identical fashion. The vena cava to be grafted was then sleeved onto each arterial end in turn 
and tied into position with 8/0 suture. Twenty-eight days after grafting, mice were euthanised 
by a rising concentration of CO2.  The neck was opened and the vein graft removed and 
placed in physiological bathing solution. 
 
Perivascular mast cell reconstitution 
In a previous study from our laboratory, we established a reliable method for reconstituting 
mast cells locally to the perivascular region. The advantage of this method is that it re-
establishes a local mast cell reconstitution in the KitW-sh/W-sh mice without mast cells being 
present elsewhere.[14] Thus, this method allows the role of perivascular mast cells to be 
investigated without the consequences of systemic mast cell reconstitution, which can include 
ectopic mast cell accumulation and abnormal distribution of mast cells in target 
organs/tissues.[10,14] Briefly, C57BL/6J mice were used as the source of bone marrow cells 
and these were cultured with mast cell-differentiating media (containing murine IL-3 and 
      
 
stem cell factor; PeproTech, New Jersey, USA) for 4 weeks as we have described 
previously.[14] To confirm that the cultured cells were in fact differentiated into mast cells, 
flow cytometry with anti-c-Kit and anti-)Fİ5,DQWLERGLHVH%LRVFLHQFH+DWILHOG8.ZDV
used.[14] To investigate the impact of local reconstitution of mast cells on neointima formation 
within the vein graft, the perivascular area of the right common carotid artery was injected 
with the bone marrow-derived mast cells (BMMCs) as follows. Briefly, the recipient KitW-
sh/W-sh mouse was anaesthetized with sodium pentobarbital as previously described and the 
common right carotid artery was exposed. BMMCs were injected around the artery (1 million 
cells per mouse). A suture of size 6/0 was used to close the wound and the animal was kept 
for 4 weeks to allow repopulation of the perivascular area with a mast cell population similar 
to that seen in wild type (C57BL/6) mice.[14] Vein graft surgery was performed 4 weeks after 
mast cell reconstitution.  
 
Histology and immunostaining 
Vein grafts were perfusion-fixed to maintain graft patency and then stored overnight in 10% 
formalin before being embedded in paraffin. For each vein graft, serial sections of 5 µm 
thickness were cut from 5 evenly divided regions from the proximal to the distal end. In all 
cases, 5 slides (1 slide from each region) were stained as outlined below and the values 
averaged for each vein graft. The advantage of this method is that the average value gives an 
indication of the value from the whole of the graft rather than one discrete area which may 
not be representative of the graft as a whole. For general and gross morphology and for 
planimetry studies, haematoxylin and eosin staining was used and the slides were 
photographed and analysed using Image pro plus software (Media Cybernetics, Marlow, UK). 
Collagen was stained by picrosirius red and visualised under polarised light. As with other 
stains used, at least 5 slides were used from the length of the graft to give a mean intensity of 
the total fluorescent signal and this value was used for comparison of collagen content 
between groups. Elastin was identified by Verhoeff Van Gieson staining and mean intensity 
of light absorption of the bluish dark stain within the neointima was quantified. To avoid 
batch-to-batch variation, for each staining protocol, all the vein graft samples were stained at 
one time. For immunostaining, slides were de-waxed and pressure-cooked in citrate buffer to 
retrieve antigens of interest. To study proliferation in vein grafts, one slide per vein graft was 
stained using an antibody to the marker Ki67 (rabbit anti-Ki67 antibody, Abcam). The 
percentage cell proliferation was presented as the ratio of Ki67 positive nuclei over total 
nuclei in the wall of the vein graft.  
      
 
 
Statistics 
In all experiments, data are presented as mean ± standard error of the mean where n refers to 
WKHQXPEHURIPLFH7RPDNHFRPSDULVRQVEHWZHHQWZRJURXSVDQXQSDLUHG6WXGHQW¶Vt-test 
was used as long as the data had a normal distribution and, for data not normally distributed, 
the non-parametric Mann Whitney test was used. To compare data from multiple groups a 
one-way analysis of variance (ANOVA) ZLWK7XNH\¶Vpost hoc test was used as appropriate. 
Statistical analyses were performed using GraphPad Prism v6.04. In all comparisons, a 
significant difference was assumed when P < 0.05. 
 
RESULTS 
Mast cells promote elastin but not collagen deposition in vein grafts by 4 weeks  
Significant collagen deposition was identified in all vein grafts at 4 weeks. The majority of 
collagen was present in the neo-adventitia and perivascular area [Figure 1A]. In contrast, 
elastin was only detected in the neointima [Figure 1B and C]. Mast cell deficiency (KitW-sh/W-
sh) had no impact on collagen deposition, but suppressed elastin deposition by 6.5 fold. Local 
mast cell reconstitution (4 weeks before vein graft implantation) rescued the impaired elastin 
deposition in KitW-sh/W-sh vein grafts (23.5 ± 4.8 vs. 3.6 ± 1.1 vs. 26.4 ± 4.4 arbitrary 
units/mm2; C57BL/6J vs. KitW-sh/W-sh vs. KitW-sh/W-sh + lcMC; P < 0.01 by one-way ANOVA). 
Mast cell deficiency in hyperlipidaemic mice induced a similar suppression of neointimal 
elastin (37.6 ± 4.0 vs. 13.4 ± 2.9 arbitrary units/mm2; apoE-/-  vs. apoE-/- KitW-sh/W-sh; P < 0.01 
E\6WXGHQW¶Vt-test). 
 
Mast cell deficiency increased chronic neointimal proliferation and thickening in apoE-/- 
mice but not in C57BL/6J mice 
Mast cell deficiency moderately suppressed neointima formation in normolipidaemic mice 4 
weeks after grafting (1.7 h 105 ± 0.2 h 105 vs. 1.1 h 105 ± 0.1 h 105 µm2; C57BL/6J vs. 
KitW-sh/W-sh; P < E\6WXGHQW¶Vt-test), but induced a 2-fold increase in the hyperlipidaemic 
mice (1.9 h 105 ± 0.2 h 105 vs. 4.2 h 105 ± 0.8 h 105 µm2; apoE-/- vs. apoE-/- KitW-sh/W-sh; P 
< E\6WXGHQW¶Vt-test; Figure 2A and B). Cell proliferation within the vein graft at 4 
weeks was very low in both C57BL/6J and KitW-sh/W-sh (2.1 ± 0.5% vs. 1.8 ± 0.3%; C57BL/6J 
vs. KitW-sh/W-sh), but significantly elevated in apoE-/-KitW-sh/W-sh compared to apoE-/- (1.9 ± 0.5% 
      
 
vs. 5.3 ± 1.4%; apoE-/- vs. apoE-/- KitW-sh/W-sh; P < 0.05 by Mann Whitney test; Figure 2A and 
C).  
 
DISCUSSION 
This study demonstrates firstly that perivascular mast cells elevate neointimal elastin 
deposition under both normolipidaemic and hyperlipidaemic conditions, and secondly that 
they suppress neointimal thickening in hyperlipidaemic mice possibly via down regulation of 
cell proliferation within the vein graft.   
 
Elastin is one of the fundamental structural proteins of the arterial wall that regulates vascular 
elasticity and stabilises smooth muscle cells.[18] The present study demonstrates that mast 
cells play a previously unrecognised role in promotion of elastin deposition during vein graft 
remodelling. The causality is demonstrated by the data showing that mast cell deficiency 
reduced, and mast cell reconstitution rescued, elastin deposition in the vein graft. Although 
the exact mechanism of how mast cells regulate elastin deposition is not yet clear, there is a 
consensus within the literature that heparin is the potential mediator. The evidence for the 
involvement of heparin is three-fold. Firstly, mast cells are the only cell type that produces 
heparin in vivo.[19] Secondly, heparin is known to promote elastogenesis and supress 
neointima hyperplasia in injured arteries and vascular grafts.[20,21] Being the most negatively 
charged molecule in biological systems, heparin covalently binds to the positively charged 
tropoelastin to accelerate tropoelastin coacervation and elastic fibre formation.[22-24] However, 
the very short half-life of heparin limits its pharmacological potency for therapeutic 
purposes.[25] Only continuous intravenous delivery,[26-28] but not short term treatment,[29] 
inhibited neointima thickening. Interestingly, perivascular delivery of heparin required a 
much smaller dose and was more effective in suppression of neointima hyperplasia,[20,25] 
which matches the source of endogenous heparin from perivascular mast cells. Thirdly, mast 
cell granules are enriched with heparin and the heparin-based particles are capable of long 
distance travel within tissue[30] which makes perivascular mast cells an ideal and indeed the 
only source for continuous heparin supply to assist vascular elastogenesis.  
 
It is intriguing that mast cell-dependent elastin deposition had a divergent impact on 
neointimal hyperplasia in normolipidaemic and hyperlipidaemic vein grafts. This could be a 
consequence of the different dynamics of neointima formation and vascular matrix 
remodelling. In normolipidaemic mice, the neointima formation is driven by acute 
      
 
inflammation and proliferation which peak within one week and are complete by 2 
weeks.[13,31] During the 3rd and 4th weeks, the neointimal proliferation decreases over 10-fold 
and the majority of the neointimal cells transdifferentiate into smooth muscle-like cells that 
initiate vascular matrix remodelling including elastin deposition.[13,14,18,31] Therefore, elastin 
is unlikely to regulate the early events of neointima formation in the normolipidaemic vein 
graft. The modest reduction in neointimal area in the KitW-sh/W-sh vein graft is attributed to the 
damped cell proliferation during the first week rather than altered elastin deposition.[14]  
 
Both our data and the literature[32] demonstrated that apoE-/- mice, when fed on normal chow 
diet, do not demonstrate any enhancement of neointimal hyperplasia. The low cell 
proliferation level in apoE-/- vein grafts at 4 weeks in the current study suggests that the 
neointima was stabilised, similar to that in C57BL/6J. These observations are in contrast with 
in vitro evidence that apoE-/- smooth muscle cells are predisposed to a higher rate of 
proliferation.[17] One clear difference between data from cell cultures and neointima 
formation in vivo is the absence of the rich extracellular matrix environment. ApoE-/- vein 
grafts at 4 weeks contained large amounts of elastin that can stabilise neointimal smooth 
muscle cells.[18] The reduction in neointimal elastin in apoE-/-KitW-sh/W-sh grafts was correlated 
with a dramatic increase in cell proliferation within the vein graft wall, suggesting that the 
presence of elastin is an important protective mechanism against chronic smooth muscle cell 
proliferation under pro-atherogenic conditions.  
 
Mast cells, as innate immune cells, are well-documented to have pro-inflammatory effects in 
many pre-clinical vascular studies.[6] Induction of mast cell activation in a pro-inflammatory 
environment, either using pharmacological activators or long term western diet in pro-
atherosclerotic mouse models (apoE-/- or LDLr-/-), was a common feature of these studies. 
The widely accepted paradigm is that high levels of pro-inflammatory factors and proteinases 
released by activated mast cells promote vascular inflammation and development of vascular 
lesions. Indeed activated mast cells may be the explanation for the clinical correlation 
between mast cell-mediated allergic disease and atherosclerosis.[33] However, the role of 
unstimulated mast cells in normal vasculature or in stable vascular disease is not fully 
understood. The current study provides the first evidence that mast cells could exert a 
positive effect in vascular remodelling via regulation of elastin deposition. Our unpublished 
data suggests that the expression of inflammatory cytokines in vein grafts during the 
remodelling stage (4 weeks after implantation) is negligible. We therefore speculate that the 
      
 
mast cell-dependent regulation of elastin is independent of immunological/inflammatory 
mechanisms, but mediated by heparin (as discussed above) or some unknown mechanisms.  
 
The mast cell-elastin-axis could potentially be extrapolated to vascular development as the 
first appearance of mast cells around the foetal aorta is before the formation of aortic elastic 
laminae.[34] This suggests that mast cells may also contribute to the foetal arteriogenesis by 
assisting formation of elastic fibres. In addition to the perivascular area, the mast cell 
population is clearly enriched in all the elastic tissue/organs including arteries, skin and lung, 
indicating a universal link between mast cells and elastin. Under pathological conditions, an 
increase of mast cell number is often associated with elastin-related tissue fibrosis.[35,36] In a 
skin photodamage model, chronic ultraviolet light exposure increases skin mast cell number 
accompanied by a 3.6 fold elevation in elastin content, which was not observed in the mast 
cell-deficient KitW/W-v mice.[37] Similar correlation was also present in human skin.[38] Non-
elastic organs, such as the liver usually hosts only a very small population of mast cells.[39] In 
liver disease, an increase of hepatic elastin is one of the most distinct features of hepatic 
fibrosis and cirrhosis,[36] correlated with a significant increase in hepatic mast cells.[39] In 
contrast to other leukocyte recruitment, the increase of mast cell number persisted with the 
chronic progress of hepatic cirrhosis,[40] suggesting the mast cell-mediated pathological 
elastin accumulation was beyond inflammatory mechanisms.  
 
Collectively, accumulating evidence suggests that the mast cell-elastin axis may be a 
universal mechanism that regulates physiological and pathological elastin metabolism. Our 
findings, in line with other literature, raise the question of whether mast cells regulate 
vascular elastin metabolism via mechanisms independent from their immunological function. 
More comprehensive investigation is required to clarify the complex role of mast cells in 
vascular development and remodelling.  
 
The current study used a mast cell-deficient mouse model (KitW-sh/W-sh) and local mast cell 
reconstitution to demonstrate that perivascular mast cells promoted neointimal elastin 
remodelling in vein grafts. Limited by the experimental period, it was not clear whether 
perivascular mast cells merely accelerated the elastin deposition in the 4-week time window, 
or permanently increased the elastin level in the neointima. Unlike the elastic lamina in 
healthy arteries, the elastic fibres in the neointima were diffuse. The presence of mast cells 
only increased the amount of elastic fibres but did not improve the structure of the matrix. 
      
 
Further experiments are required to clarify whether the quantitative increase in elastin content 
has a positive impact on vascular compliance and vasomotor function, which may also 
influence the neointima hyperplasia.  
 
In conclusion, this is the first study to demonstrate the mast cell-dependent regulation of 
elastin deposition in vein grafts, and subsequent suppression of chronic vein graft hyperplasia 
in hyperlipidaemic mice. This study sheds new light on the function of perivascular mast 
cells on vascular lesion formation and remodelling, and provides new targets for therapeutic 
intervention for vein graft failure and other stenotic vascular disease.  
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Figure 1: Mast cell deficiency suppressed elastin deposition in vein graft. (A) Picrosirus 
red staining demonstrated that both C57BL/6J and KitW-sh/W-sh vein grafts synthesised large 
amount of collagen (in green, yellow and red colour) in the adventitia and perivascular 
connective tissue by 4 weeks. No statistical difference was detected in collagen content 
between groups. (B, C) Elastin deposition was restricted to the vein graft neointima 
(visualised by Verhoeff Van Gieson staining, indicated by arrows). Mast cell deficient KitW-
sh/W-sh vein grafts contained a significantly lower level of elastin versus congenic C57BL/6J 
vein grafts, which was rescued by local mast cell reconstitution. Mast cell deficiency in 
hyperlipidaemic mice (apoE-/-) also significantly suppressed elastin deposition in the vein 
graft by 4 weeks. n = 6; **P < 0.01. One-way analysis of variance plus Tukey post hoc test 
ZDVXVHGIRUPXOWLSOHJURXSFRPSDULVRQDQGXQSDLUHG6WXGHQW¶Vt test for two group 
comparison   
 
      
 
Figure 2: Mast cell deficiency in hyperlipidaemic mice increased neointima area with 
elevated chronic cell proliferation. (A) Representative images of cell proliferation in 4-
week-old vein grafts. Proliferating cells were labelled using an antibody against Ki67 (green) 
and cell nuclei by DAPI (blue). The neointimal area in apoE-/- KitW-sh/W-sh vein grafts was 
significantly higher than all other groups (B), associated with elevated cell proliferation by 4 
weeks (C). n > 6 for all groups; **P < 0.01 by one-way analysis of variance plus Tukey post 
hoc test 
 
 
 
